CYP2D6 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, the CYP2D6 GA genotype was strongly associated with a reduced risk of developing Ph-ve CML (p < 0.005) with a frequency of 50% in Ph-ve patients and 93% in the control group.